Technologies

The Biocrystal Facility, a large multidisciplinary laboratory established at the Institute of Molecular Biology and Pathology (IBPM) of CNR, in collaboration with the Biochemistry Department of Sapienza University aims at supporting the italian scientists and the pharmaceutical companies in the research to find new drug and vaccine against the endemic and epidemic diseases through structure-based drug design.

The dramatic global health emergency due to the SARS-CoV-2 pandemic requires new diagnostic devices capable of identifying the presence of virus particles in patient biological samples. In this direction, the development of an innovative low-cost test, which provides the result within a few minutes, which is reproducible and which can reveal the direct presence of even a few viral particles, would be of fundamental importance for the monitoring and containment of the pandemic.

The portable device is intended to assess exposure to electromagnetic fields produced by an MRI equipment. The device (dosimeter) allows to improve the analysis and study of the problems related to the exposure of the operators, starting from the technical-scientific aspects related to the exposure, also allowing to create a manual of best practices as well as to improve the professional training of operators.

The virtual dynamic docking, carried out in the MOLBD3 lab of the Institute of Biophysics, allows the identification of new drugs through the structural information deriving from the study of target proteins, responsible for some human pathologies. In particular, we screen drugs or small molecules (commercial/own libraries) against known protein sites, surface cavities, surfaces of protein-protein interactions (fixed/rigid hotspots) or structural transition states (dynamic hotspots).

Our innovative proposal involves an educational robotics training program, resulting from an experimental research that combines traditional educational approaches with the utilization of robotics. Specifically, the educational robot Thymio, developed by EPFL, serves as a facilitator in the learning process to enhance School Readiness.

Plants have a huge potential to contribute to the solution of a large number of issues facing the modern world, ranging from a poor crop yields and problems caused by global climate changing. Our team has been on the forefront of the PCR and NGS applications to plant responses to biotic and abiotic stress. As experts in genomics and plant pathology we are able to accelerate the understanding and use of plant genes and resources.

We developed a procedure aimed at simultaneously treating thousands of C.elegans model organisms, from eggs to old adult, in liquid, in 96- or 384-well plates. This procedure can be used to perform drug and toxicological screening of millions of compounds, in very small volumes and on millions of animals. Thanks to easy handling, semi-automatic analysis can be performed using plate readers or High Content Screening instruments.

The Nikon reference centre at IBPM ( www.imagingplatformibpmcnr.it ) is a microscopy platform for high resolution imaging of fixed samples and live cells (time-lapse video recording, both wide field and confocal spinning disk). Multimodal (fluorescence and transmitted light) and multidimensional (in x,y,z, 4 wavelengths, over time) acquisition modes are in place.

Our idea come from the improving of the traceability technique in agro-food fisheries industries through the application of omics technologies in microbiota studies.  These latter would be capable of exploiting the huge pool of biological molecules contained in fishery resources (e.g. nucleic acids, proteins, metabolites) and use them as a powerful tools for the identification and reconstruction of fishery history, from the sea to the table.

In the last years, genetics played a strategic role in the identification of therapeutic targets for complex diseases. Genetic studies identified thousands of variants contributing to disease onset and/or to the influence of measurable features (phenotypes) impacting health. The mechanism of action by which they modulate diseases and phenotypes is still unknown for the vast majority.

Detection devices for the presence of molecules of interest (analytes) enjoyed a renewed burst with the introduction of biological components (biosensors). Their high specificity is often used in various fields, from environmental monitoring and biomedicine to the protection and promotion of agri-food products. However, the high cost of production and the lack of compatibility with mass sampling (high-throughput) sometimes limit their use.

This technology concerns the development of new eco-sustainable UV physical/mineral filters with the aim of offering important innovations per the cosmetic sector. This, encouraged by European initiatives in the Green-Deal context, is constantly looking for new components with improved protection of the human health and the environment.

Lifeshell is an anti-seismic furniture construction concept, which can be used for making wardrobes, tables, desktops, beds. It’s made by timber based panels: highly resistant and flexible, relatively lightweight and inexpensive. Lifeshell benefits from the natural wood elasticity and from smart connections for dissipating the great impact energies occurring during an earthquake. Lifeshell has been designed for resisting partial building collapses, and to provide a safe shell where inhabitants can find refuge.

It enables a systemic and evolutionary development of people, organisations and territories by overcoming the criticality of traditional approaches, which get stuck because of rationalistic reductions in complexity, as well as lack of motivation. This responds to the social sustainability needs highlighted by the UN 2030 agenda. The methodology is based on 3 pillars:

Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.